Stock Scorecard



Stock Summary for Bolt Biotherapeutics Inc (BOLT) - $0.57 as of 11/20/2024 7:51:44 PM EST

Total Score

16 out of 30

Currently on the following lists
Small Cap Stock List
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for BOLT

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BOLT

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BOLT

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BOLT

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BOLT (18 out of 90)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 1
Stock Price Trend (Max of 10) 0
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 10
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 3
Price to Earnings (Max of 10) 0

Latest News for for BOLT

Bolt Biotherapeutics, Inc. ( BOLT ) Reports Q3 Loss, Tops Revenue Estimates 11/12/2024 10:35:00 PM
Arcturus Therapeutics ( ARCT ) Reports Q3 Loss, Lags Revenue Estimates 11/7/2024 10:55:00 PM
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting 11/7/2024 3:00:00 PM
Bolt Biotherapeutics Announces Changes to its Board of Directors - Bolt Biotherapeutics ( NASDAQ:BOLT ) 9/4/2024 8:05:00 PM
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Bolt Biotherapeutics ( NASDAQ:BOLT ) 9/2/2024 2:50:00 PM
BOLT DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action - BOLT - Bolt Biotherapeutics ( NASDAQ:BOLT ) 9/1/2024 1:11:00 PM
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm - CVS Health ( NYSE:CVS ) , Bolt Biotherapeutics ( NASDAQ:BOLT ) 8/31/2024 1:00:00 AM
BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Bolt Biotherapeutics ( NASDAQ:BOLT ) 8/30/2024 6:00:00 PM
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt - Bolt Biotherapeutics ( NASDAQ:BOLT ) 8/30/2024 12:49:00 AM
BOLT FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action - BOLT - Bolt Biotherapeutics ( NASDAQ:BOLT ) 8/28/2024 9:30:00 PM

Financial Details for BOLT

Company Overview

Ticker BOLT
Company Name Bolt Biotherapeutics Inc
Country USA
Description Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the discovery, development and commercialization of pharmaceutical products. The company is headquartered in Redwood city, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 0.57
Price 4 Years Ago 0.00
Last Day Price Updated 11/20/2024 7:51:44 PM EST
Last Day Volume 58,935
Average Daily Volume 118,387
52-Week High 1.56
52-Week Low 0.54
Last Price to 52 Week Low 5.56%

Valuation Measures

Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -0.82
Free Cash Flow Ratio 0.26
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 3.16
Total Cash Per Share 2.21
Book Value Per Share Most Recent Quarter 2.96
Price to Book Ratio 0.30
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 1.92
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 0
Analyst Strong Buy Ratings 0

Share Statistics

Total Shares Outstanding 38,273,000
Market Capitalization 21,815,610
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 21.45%
Reported EPS 12 Trailing Months -1.71
Reported EPS Past Year -1.14
Reported EPS Prior Year -1.83
Net Income Twelve Trailing Months -65,085,000
Net Income Past Year -69,197,000
Net Income Prior Year -88,098,000
Quarterly Revenue Growth YOY -11.00%
5-Year Revenue Growth 150.02%
Operating Margin Twelve Trailing Months -14.93

Balance Sheet

Total Cash Most Recent Quarter 84,400,000
Total Cash Past Year 128,600,000
Total Cash Prior Year 192,800,000
Net Cash Position Most Recent Quarter 84,400,000
Net Cash Position Past Year 128,600,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 112,741,000
Total Stockholder Equity Prior Year 171,506,000
Total Stockholder Equity Most Recent Quarter 72,031,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -61,171,000
Free Cash Flow Per Share Twelve Trailing Months -1.60
Free Cash Flow Past Year -69,731,000
Free Cash Flow Prior Year -78,457,000

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.02
MACD Signal -0.01
20-Day Bollinger Lower Band 0.56
20-Day Bollinger Middle Band 0.66
20-Day Bollinger Upper Band 0.77
Beta 0.92
RSI 32.62
50-Day SMA 1.47
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 11/20/2024 7:52:33 PM EST